Antiretroviral Pharmacokinetics in Mothers and Breastfeeding Infants from 6 to 24 Weeks Post-Partum: Results of the Ban Study

Abstract

Background

An intensive, prospective, open-label pharmacokinetic (PK) study in a subset of HIV-infected mothers and their uninfected infants enrolled in the Breastfeeding, Antiretroviral and Nutrition (BAN) Study was performed to describe drug exposure and antiviral response.

Methods

Women using Combivir® (zidovudine [ZDV] + lamivudine [3TC]) + Aluvia® (lopinavir/ritonavir [LPV/ RTV]) were enrolled. Breast milk (BM), mother plasma (MP) and infant plasma (IP) samples were obtained over 6 h after observed dosing at 6, 12 or 24 weeks post-partum for drug concentrations and HIV RNA.

Results

A total of 30 mother/infant pairs (10 each at 6, 12 and 24 weeks post-partum) were enrolled. Relative to MP, BM concentrations of ZDV and 3TC were 35% and 21% higher, respectively, whereas LPV and RTV were 80% lower. Only 3TC was detected in IP with concentrations 96% and 98% lower than MP and BM, respectively. Concentrations in all matrices were similar at 6–24 weeks. The majority (98.3%) of BM concentrations were >HIV^wt IC₅₀, with one having detectable virus. There was no association between PK parameters and MP or BM HIV RNA.

Conclusions

ZDV and 3TC concentrated in BM whereas LPV and RTV did not, possibly due to protein binding and drug transporter affinity. Undetectable to low antiretroviral concentrations in IP suggest prevention of transmission while breastfeeding may be due to antiretroviral effects on systemic or BM HIV RNA in the mother. Low IP 3TC exposure may predispose an infected infant to HIV resistance, necessitating testing and treating infants early.

References

Nduati

, Richardson

B.A.

, John

Effect of breastfeeding on mortality among HIV-1 infected women: a randomised trial. Lancet 2001; 357: 1651–1655.

Thior

, Lockman

, Smeaton

L.M.

Breastfeeding plus infant zidovudine prophylaxis for 6 months vs formula feeding plus infant zidovudine for 1 month to reduce mother-to-child HIV transmission in Botswana. A randomized trial: the Mashi Study. JAMA 2006; 296: 794–805.

UNAIDS. Global report. UNAIDS report on the global AIDS epidemic 2013. (Updated November 2013. Accessed 19 September 2014.) Available from http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2013/gr2013/UNAIDS_Global_Report_2013_en.pdf.

Week Extended-Dose Nevirapine (SWEN) Study Team. Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials. Lancet 2008; 372: 300–313.

Jamieson

D.J.

, Chasela

C.S.

, Hudgens

M.G.

Maternal and infant antiretroviral regimens to prevent postnatal HIV-1 transmission: 48-week follow-up of the BAN randomised, controlled trial. Lancet 2012; 379: 2449–2458.

Kesho Bora Study Group. Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial. Lancet Infect Dis 2011; 11: 171–180.

Kilewo

, Karlsson

, Massawe

Prevention of mother-to-child transmission of HIV-1 through breastfeeding by treating infants prophylactically with lamivudine in Dar es Salaam, Tanzania: the Mitra Study. J Acquir Immune Defic Syndr 2008; 48: 315–323.

Kilewo

, Karlsson

, Ngarina

Prevention of mother-to-child transmission of HIV-1 through breastfeeding by treating mothers with triple antiretroviral therapy in Dar es Salaam, Tanzania: the Mitra Plus study. J Acquir Immune Defic Syndr 2009; 52: 406–416.

Marazzi

C.M.

, Germano

, Liotta

Implementing anti-retroviral triple therapy to prevent HIV mother-to-child transmission: a public health approach in resource-limited settings. Eur J Pediatr 2007; 166: 1305–1307.

10.

Peltier

C.A.

, Ndayisaba

G.F.

, Lepage

Breastfeeding with maternal antiretroviral therapy or formula feeding to prevent HIV postnatal mother-to-child transmission in Rwanda. AIDS 2009; 23: 2415–2423.

11.

Shapiro

R.L.

, Hughes

M.D.

, Ogwu

Antiretroviral regimens in pregnancy and breast-feeding in Botswana. N Engl J Med 2010; 362: 2282–2294.

12.

Taha

T.E.

, Li

, Hoover

D.R.

Postexposure prophylaxis of breastfeeding HIV-exposed infants with antiretroviral drugs to age 14 weeks: updated efficacy results of the PEPI-Malawi trial. J Acquir Immune Defic Syndr 2011; 57: 319–325.

13.

Thomas

T.K.

, Masaba

, Borkowf

C.B.

Triple-antiretroviral prophylaxis to prevent mother-to-child HIV transmission through breastfeeding–the Kisumu Breastfeeding Study, Kenya: a clinical trial. PLoS Med 2011; 8: e1001015.

14.

Vyankandondera

, Luchters

, Hassink

, Pakker

, Mmiro

, Okong

Simba – stopping infection from mother to child via breastfeeding in Africa. 2nd International AIDS Society Conference on HIV Pathogenesis. 13–16 July 2003, Paris, France. Abstract LB07.

15.

WHO. The use of antiretroviral drugs for treating and preventing HIV infection. Recommendations for a publica health approach. (Updated June 2013. Accessed 19 September 2014.) Available from http://apps.who.int/iris/bitstream/10665/85321/1/9789241505727_eng.pdf.

16.

Corbett

, Martinson

, Rezk

Lopinavir/ritonavir concentrations in breast milk and breast-feeding infants. 16th Conference on Retroviruses and Opportunistic Infections. 8–11 February 2009, Montreal, Canada. Abstract 947.

17.

Corbett

, Martinson

, Rezk

Antiretroviral drug concentrations in breast milk and breastfeeding infants. 15th Conference on Retroviruses and Opportunistic Infections. 3–6 February 2008, Boston, MA, USA. Poster 648.

18.

Mirochnick

, Thomas

, Capparelli

Antiretroviral concentrations in breast-feeding infants of mothers receiving highly active antiretroviral therapy. Antimicrob Agents Chemother 2009; 53: 1170–1176.

19.

Schneider

, Peltier

, Gras

Efavirenz in human breast milk, mothers’, and newborns’ plasma. J Acquir Immune Defic Syndr 2008; 48: 450–454.

20.

Shapiro

R.L.

, Holland

D.T.

, Capparelli

Antiretroviral concentrations in breast-feeding infants of women in Botswana receiving antiretroviral treatment. J Infect Dis 2005; 192: 720–727.

21.

Palombi

, Pirillo

M.F.

, Andreotti

Antiretroviral prophylaxis for breastfeeding transmission in Malawi: drug concentrations, virological efficacy and safety. Antivir Ther 2012; 17: 1511–1519.

22.

Rezk

N.L.

, White

, Bridges

A.S.

Studies on antiretroviral drug concentrations in breast milk: validation of a liquid chromatography-tandem mass spectrometric method for the determination of 7 anti-human immunodeficiency virus medications. Ther Drug Monit 2008; 30: 611–619.

23.

Frontier Science and Technology Rsearc Foundation, Inc. National Institute for Allergy and Infectious Diseases, Division of AIDS. Clinical pharmacology quality assurance antiretroviral proficiency testing program. (Accessed 19 September 2014.) Available from www.fstrf.org.

24.

KKGT. In association for quality assessment in TDM and clinical toxicology. A section of the Dutch Foundation for quality assessment in medical laboratories. (Accessed 19 September 2014.) Available from www.kkgt.nl.

25.

Moore

K.H.

, Shaw

, Laurent

A.L.

Lamivudine/zidovudine as a combined formulation tablet: bioequivalence compared with lamivudine and zidovudine administered concurrently and the effect of food on absorption. J Clin Pharmacol 1999; 39: 593–605.

26.

Kaletra (lopinavir/ritonavir). Package insert 2013. Abbott Laboratories

North Chicago, IL, USA.

27.

Veldkamp

A.I.

, van Heeswijk

R.P.

, Mulder

J.W.

Steady-state pharmacokinetics of twice-daily dosing of saquinavir plus ritonavir in HIV-1-infected individuals. J Acquir Immune Defic Syndr 2001; 27: 344–349.

28.

Anderson

G.D.

Using pharmacokinetics to predict the effects of pregnancy and maternal-infant transfer of drugs during lactation. Expert Opin Drug Metab Toxicol 2006; 2: 947–960.

29.

Riant

, Urien

, Albengres

, Duche

J.C.

, Tillement

J.P.

High plasma protein binding as a parameter in the selection of betablockers for lactating women. Biochem Pharmacol 1986; 35: 4579–4581.

30.

Olagunju

, Owen

, Cressey

T.R.

Potential effect of pharmacogenetics on maternal, fetal and infant antiretroviral drug exposure during pregnancy and breastfeeding. Pharmacogenomics 2012; 13: 1501–1522.

31.

Alcorn

, Lu

, Moscow

J.A.

, McNamara

P.J.

Transporter gene expression in lactating and nonlactating human mammary epithelial cells using real-time reverse transcription-polymerase chain reaction. J Pharmacol Exp Ther 2002; 303: 487–496.

32.

Fiscus

S.A.

, Aldrovandi

G.M.

Virologic determinants of breast milk transmission of HIV-1. Adv Exp Med Biol 2012; 743: 69–80.